Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CLTC | Q00610 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | BRD1 | O95696 | 2/20 | 0.41 |
| ▸ | TAF1 | P21675 | 2/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163766 | 0.84 | CYP2C9 (0.57) | CYP2C9CYP2C19CLTCL3MBTL1CA12 | |
| SCHEMBL5159753 | 0.81 | CYP2C9 (0.55) | CYP2C9CYP2C19CLTCL3MBTL1CA12 | |
| SCHEMBL5533325 | 0.81 | CYP2C9 (0.54) | CYP2C9CYP2C19CLTCL3MBTL1CA12 | |
| SCHEMBL5158664 | 0.80 | CLTC (0.76) | CYP2C9CYP2C19CLTCL3MBTL1CA12 | |
| SCHEMBL14502327 | 0.77 | TDP1 (0.56) | CYP2C9CYP2C19L3MBTL1CA12CA9 | |
| SCHEMBL5156075 | 0.77 | ALDH1A1 (0.73) | CYP2C9CYP2C19L3MBTL1CA12CA9 | |
| SCHEMBL5163261 | 0.76 | CYP2C19 (0.49) | CYP2C9CYP2C19CLTCL3MBTL1CA12 | |
| SCHEMBL5153048 | 0.75 | CYP2C9 (0.46) | CYP2C9CYP2C19CLTCL3MBTL1CA12 | |
| SCHEMBL5150071 | 0.74 | POLB (0.66) | CYP2C9CYP2C19L3MBTL1RXFP1MEN1 | |
| SCHEMBL5159082 | 0.73 | KMT2A (0.61) | CYP2C9CYP2C19L3MBTL1RXFP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | claimed |
| WO-2007030939-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | claimed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | US | disclosed |
| WO-2007030939-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123514-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | CYP2C9 4879/4885CYP2C19 4871/4885CLTC 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.